Arrowhead Pharmaceuticals (ARWR) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
18 figures withheld by our checks. Each blank figure names its reason.
105.4mn → 141.6mn diluted shares since FY22. Rising share count dilutes EPS. Growth must outrun it.
−47.1% YoY in FY26 · 2.7% of revenue.
$56.0M returned vs $−283.9M of FCF in FY26. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.
-161¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Net margin -160.6% is below the sector median. This filer reports no gross profit line, so that margin is not drawn.
| Line item | TTM † | FY26 | FY25 | FY24 | FY23 | FY22 | YoY | CAGR 22→26 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 450.8 | 450.8 | 829.4 | 7.1 | 240.7 | 243.2 | ▼45.6% | +16.7% |
Cost of revenue | 1.8 | 1.8 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | — | —A | —B | —B | —B | —B | — | — |
Research & development | 739.1 | 739.1 | 607.2 | 505.9 | 353.2 | 297.3 | ▲21.7% | +25.6% |
Selling, general & admin | 202.0 | 202.0 | 123.9 | 98.8 | 92.5 | 124.4 | ▲63.0% | +12.9% |
Total operating expenses | 1,156.2 | 1,156.2 | 731.1 | 604.6 | 445.7 | 421.7 | ▲58.1% | +28.7% |
Operating incomefeeds ROC rank | −707.2 | −707.2 | 98.3 | −601.1 | −205.0 | −178.5 | — | — |
Other income, net | −16.7 | −16.7 | −46.8 | −11.4 | −1.5 | 5.8 | — | — |
Pretax income | −723.9 | −723.9 | 51.5 | −612.5 | −206.5 | −172.7 | — | — |
Income tax | −6.8 | −6.8 | 21.4 | −2.8 | 2.8 | 3.8 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −724.2 | −724.2 | −1.6 | −599.5 | −205.3 | −176.1 | ▼44302.6% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −5.11 | −5.11 | −0.01 | −5.00 | −1.92 | −1.67 | — | — |
Diluted shares (mn) | 141.63 | 141.63 | 133.76 | 119.78 | 106.75 | 105.43 | ▲5.9% | +7.7% |
| Margins | ||||||||
Gross margin98th pct in Healthcare | — | —A | —B | —B | —B | —B | — | — |
Operating margin | −156.9% | −156.9% | 11.9% | −8463.5% | −85.2% | −73.4% | ▼168.7pp | −83.5pp |
Net margin8th pct in Healthcare | −160.6% | −160.6% | −0.2% | −8441.2% | −85.3% | −72.4% | ▼160.4pp | −88.3pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Arrowhead Pharmaceuticals' revenue last fiscal year?
Arrowhead Pharmaceuticals reported revenue of $450.8M in fiscal 2026, down 45.6% from fiscal 2025.
What was Arrowhead Pharmaceuticals' net income?
Arrowhead Pharmaceuticals reported net income of −$724.2M in fiscal 2026, a net margin of −160.6%.

